Sarcoma  >>  Tibsovo (ivosidenib)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tibsovo (ivosidenib) / Servier
NCT02073994: Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Checkmark From P1 study of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: From P1 study of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies at ASCO 2018 [screenshot]
Checkmark From study for recurrent or progressive IDH1 mutant glioma at SNO 2017 [screenshot]
Nov 2017 - Nov 2017: From study for recurrent or progressive IDH1 mutant glioma at SNO 2017 [screenshot]
Checkmark Frst data from expansion cohort in cholangiocarcinoma at ASCO 2017
More
Completed
1
174
Europe, US
AG-120
Institut de Recherches Internationales Servier
Cholangiocarcinoma, Chondrosarcoma, Glioma, Other Advanced Solid Tumors
01/24
01/24

Download Options